Castrate-resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-resistant Prostate cancer
Open for enrollment
To compare the overall survival benefit of docetaxel and prednisone with and without lenalidomide as first-line therapy in chemotherapy-naïve metastatic castrate-resistant prostate cancer patients
Screening, weekly visits on cycles 1 and 2; 1 visit on cycle 3 and beyond until disease progression.
Isabella Rodrigues, PhD
Clinical Research Coordinator